摘要
目的探讨人表皮生长因子受体-2(HER-2)与细胞增殖抗原Ki67在乳腺癌组织中的表达情况及其与临床特征的关系。方法选取103例乳腺癌患者,获得组织标本,采用免疫组化方法检测HER-2与Ki67的表达水平,并分析其与临床特征之间的关系。结果 103例乳腺癌患者中HER-2、Ki67染色阳性者分别有68例和78例,阳性率分别为66.02%和75.73%。TNM分期、淋巴结转移情况以及雌激素受体(ER)表达均影响HER-2表达(P﹤0.05)。Ki67阳性表达率在不同TNM分期和淋巴结转移情况的患者中比较,差异有统计学意义(P﹤0.05)。结论 HER-2和Ki67在乳腺癌组织中与患者的TNM分期和淋巴结转移情况相关,可作为重要的临床检测指标。
Objective To investigate the expression of human epidermal growth factor receptor-2（HER-2） and cell proliferation antigen Ki67 in breast cancer tissues and its relationship with clinical pathology. Method 103 cases of breast cancer patients were included in the study, from whom the tissue samples were collected, the positive expression of HER-2 and Ki67 were detected by immunohistochemistry, and the correlation between the positive expression and clinical pathology was analyzed. Result The number of cases with positive expression of HER-2 and Ki67 in the 103 breast cancer patients were 68 and 78, respectively. The positive rates were 66.02% and 75.73%, respectively. Clinical stage,lymph node metastasis and expression of progesterone receptor（ER） influenced the expression of HER-2（P〈0.05）, while clinical stage and lymph node metastasis were significantly associated with the expression of Ki67（P〈0.05）. Conclusion Human epidermal growth factor receptor-2 and cell proliferation antigen Ki67 are correlated with patients＇ clinical staging and lymph node metastasis in breast cancer tissues, and are essential in clinical testing.
出处
《癌症进展》
2016年第9期889-891,共3页
Oncology Progress
关键词
乳腺癌
人表皮生长因子受体-2
细胞增殖抗原
临床特征
breast cancer
human epidermal growth factor receptor-2
cell proliferation antigen
clinical pathology
